Our research has limitations, such as dependence on public databases, inadequate experimental validation, small sample sizes for specific cancers, and unclear mechanisms of HSD17B10’s interactions with the epigenetic and immune microenvironments [37]. Here, HSD17B10 is linked to cancer.